# US 2023/0272489 A1 · Tumor organoid culture compositions, systems, and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272489 A1
- Document ID: US20230272489A1
- Status: Published application
- Kind: A1
- Application number: 18/300,253
- Filed: 2023-04-13
- Published: 2023-08-31
- Earliest claimed: 2019-11-22
- Assignees: Tempus Labs, Inc.
- Applicants: Tempus Labs, Inc.
- Inventors: Ameen Salahudeen; Verónica Sánchez Freire; Brandon L. Mapes
- Web page: https://patentgrep.com/patent/US20230272489A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12M 23/12: {Well or multiwell plates (C12M25/04 takes precedence)}
- C12N 5/0691: {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- G01N 33/5091: {for testing the pathological state of an organism}
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/38: Vitamins
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/117: Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/33: Insulin
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2509/10: Mechanical dissociation
- C12N 2513/00: 3D culture
- C12N 2521/10: Sound, e.g. ultrasounds
- C12N 2527/00: Culture process characterised by the use of mechanical forces, e.g. strain, vibration
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/6869: Methods for sequencing
- C12Q 2600/156: Polymorphic or mutational markers
- G16B 40/20: Supervised data analysis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).

## Claims

### Claim at position 1

-209. (canceled)

### Claim 210

A method for culturing tumor organoids, the method comprising:
a) culturing one or more tumor organoids in an organoid culture medium having less than 500 ng/mL R-spondins, wherein each respective tumor organoid in the one or more tumor organoids is derived from one or more cells of a tumor sample;
b) determining a reference genomic variant profile, wherein the reference genomic variant profile comprises for each respective genomic variant in a plurality of genomic variants identified in the tumor sample, a variant allele fraction for the respective genomic variant;
c) determining a first organoid genomic variant profile of the one or more tumor organoids, wherein the first organoid genomic variant profile comprises, for each respective genomic variant in a plurality of genomic variants identified in the one or more tumor organoids, a variant allele fraction for the respective genomic variant; and
d) confirming at least a 65% concordance in the clonal diversity of the one or more tumor organoids and the tumor sample by comparing each variant allele fraction for each respective genomic variant of the tumor sample to the corresponding variant allele fraction for the corresponding genomic variant of the one or more tumor organoids, across a plurality of genomic variants found in both the reference genomic profile and the first organoid genomic variant profile.

### Claim 211 (depends on 210)

The method of claim 210, wherein the tumor sample comprises biopsied material from a plurality of regions of a tumor from the subject.

### Claim 212 (depends on 210)

The method of claim 210, wherein the reference genomic variant profile is determined using nucleic acids obtained from the tumor sample, and the first organoid genomic variant profile is determined using nucleic acids obtained from the one or more tumor organoids.

### Claim 213 (depends on 210)

The method of claim 210, wherein the plurality of genomic variants identified in both the tumor sample and the one or more tumor organoids comprise a plurality of somatic variants.

### Claim 214 (depends on 213)

The method of claim 213, wherein the plurality of somatic variants identified in both the tumor sample and of the one or more tumor organoids comprise a single nucleotide variant.

### Claim 215 (depends on 213)

The method of claim 213, wherein the plurality of somatic variants identified in both the tumor sample and of the one or more tumor organoids comprise a point mutation or a nonsense mutation.

### Claim 216 (depends on 213)

The method of claim 213, wherein the plurality of somatic variants identified in both the tumor sample and of the one or more tumor organoids comprise a frame shift mutation.

### Claim 217 (depends on 213)

The method of claim 213, wherein the plurality of somatic variants identified in both the tumor sample and of the one or more tumor organoids comprise a deletion mutation, an insertion mutation, or a duplication mutation.

### Claim 218 (depends on 210)

The method of claim 210, wherein the plurality of genomic variants identified in both the tumor sample and of the one or more tumor organoids each comprise at least 20 genomic variants.

### Claim 219 (depends on 210)

The method of claim 210, wherein the tumor is an anal cancer, a basal cell skin cancer, a squamous cancer, a breast cancer, a bladder cancer, a cervical cancer, an endometrial cancer, a head and neck cancer, a hepatobiliary cancer, a kidney cancer, a gastric cancer, a lung cancer, a mesothelial cancer of the pleural cavity, a mesothelial cancer of the peritoneal cavity, an ovarian cancer, or a prostate cancer

### Claim 220 (depends on 210)

The method of claim 210, wherein in d), the confirming is of at least a 70% concordance in the clonal diversity of the one or more tumor organoids and the tumor sample.

### Claim 221 (depends on 210)

The method of claim 210, wherein in d), the confirming is of at least a 80% concordance in the clonal diversity of the one or more tumor organoids and the tumor sample.

### Claim 222 (depends on 210)

The method of claim 210, wherein in d), the confirming is of at least a 90% concordance in the clonal diversity of the one or more tumor organoids and the tumor sample.

### Claim 223 (depends on 210)

The method of claim 210, wherein in d), the confirming is of at least a 95% concordance in the clonal diversity of the one or more tumor organoids and the tumor sample.

### Claim 224 (depends on 210)

The method of claim 210, wherein the organoid culture medium comprise one or more growth factors selected from the following:
a) Noggin,
b) EGF and Noggin, and
c) EGF, Noggin, FGF7 and FGF10.

### Claim 225 (depends on 224)

The method of claim 224, wherein the organoid culture medium further comprises a plurality of molecular inhibitors comprising a Rho kinase inhibitor, a transforming growth factor-beta inhibitor and a MAP kinase inhibitor.

### Claim 226 (depends on 210)

The method of claim 210, wherein the method further comprises:
e) exposing the one or more tumor organoids to a therapeutic agent; and
f) after exposing one or more tumor organoids to the therapeutic agent, evaluating a property of the exposed tumor organoid cell line.

### Claim 227 (depends on 226)

The method of claim 226, wherein the evaluating in f) comprises:
determining a second organoid genomic variant profile of the one or more tumor organoids after exposure of the one or more tumor organoids to the therapeutic agent, wherein the second organoid genomic variant profile comprises, for each respective genomic variant identified in a plurality of genomic variants identified in the tumor organoid cell line after exposure to the therapeutic agent, a variant allele fraction for the respective genomic variant; and
evaluating a difference or similarity between the first organoid genomic variant profile and the second organoid genomic variant profile.

### Claim 228 (depends on 227)

The method of claim 227, wherein the second organoid genomic variant profile is determined using nucleic acids isolated from the at least one tumor organoid in the tumor organoid cell line after exposure of the tumor organoid cell line to the therapeutic agent.

### Claim 229 (depends on 227)

The method of claim 227, wherein the second organoid genomic variant profile is determined using nucleic acids isolated from the organoid culture medium after exposure of the tumor organoid cell line to the therapeutic agent.

### Claim 230 (depends on 227)

The method of claim 227, wherein the evaluating the difference or similarity includes determining which somatic variants experienced a threshold level of change between the first organoid genomic variant profile and the second organoid genomic variant profile.

### Claim 232 (depends on 226)

The method of claim 226, wherein the method further comprises assigning a therapy to the subject based on a property of the one or more tumor organoids.
